Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Anti-Tumoral Effect of Β-D-Mannuronic Acid (M2000) As a Novel Nsaid on Treg Cells Frequency and Mmp-2, Mmp-9, Ccl22 and Tgfβ1 Gene Expression in Pre-Surgical Breast Cancer Patients Publisher Pubmed



Kashefi S1 ; Ahmadi H2 ; Omranipour R2, 3 ; Mahmoodzadeh H3 ; Jafarnezhadansariha F1 ; Zavareh FT1, 3 ; Mirshafiey A1, 4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Immunology, School of Public Health, Tehran University of Medical Science, Tehran, Iran
  2. 2. Breast Disease Research Center (BDRC), Tehran University of Medical Science, Tehran, Iran
  3. 3. Department of Surgical Oncology, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran

Source: Iranian Journal of Allergy# Asthma and Immunology Published:2019


Abstract

With respect to the role of chronic inflammation in the induction and progression of breast cancer (BC). The relationship between tumor and tumor microenvironment may be a hopeful strategy for BC therapy. According to the effect of β-D-Mannuronic acid (M2000) as a novel non-steroidal anti-inflammatory drug (NSAID) on BC murine model and 4T1 cell line, we started to study that was a phase II, randomized, controlled clinical trial. 24 women with BC were included in this study and were followed by fixed oral doses of M2000, 500 mg two times a day (6-8 weeks). Blood samples were collected at baseline and weeks 6-8. To compare the patterns of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), C-C motif chemokine ligand 22 (CCL22) and The transforming growth factor-beta 1 (TGFβ1) gene expression and T regulatory cells (Tregs) frequency of healthy women normal controls with BC patients, a set of 10 blood samples of women healthy volunteers was collected. The gene expression was evaluated by quantitative Real-time PCR (qRT-PCR) and the frequency of Tregs was assessed by flow cytometry. Our results showed, reduction in MMP-2 (p=0.08), MMP-9 (p=0.03), CCL22 (p=0.003) and TGFβ1 (p=0.1) gene expression and Tregs frequency (p=0.01) which play a main role in the development of chronic inflammation, angiogenesis, tumorigenesis and metastasis. Our findings demonstrated that M2000 therapy as a novel designed NSAID had valuable therapeutic effects on BC. No adverse effects were observed following the use of M2000 after 6-8 weeks. Copyright © February 2019, Iran J Allergy Asthma Immunol. All rights reserved.
Related Docs
View other Related Docs
1. A Randomized, Controlled, Phase Ii Clinical Trial of Β-D-Mannuronic Acid (M2000) in Pre-Surgical Breast Cancer Patients at Early Stage (T1-T2), Clinical and Experimental Pharmacology and Physiology (2019)
2. Targeting of Crosstalk Between Tumor and Tumor Microenvironment by Β-D Mannuronic Acid (M2000) in Murine Breast Cancer Model, Cancer Medicine (2017)
3. Influence of Β-D-Mannuronic Acid, As a New Member of Non-Steroidal An-Ti-Inflammatory Drugs Family, on the Expression Pattern of Chemokines and Their Receptors in Rheumatoid Arthritis, Current Drug Discovery Technologies (2021)
4. International Multicenter Randomized, Placebo-Controlled Phase Iii Clinical Trial of Β-D-Mannuronic Acid in Rheumatoid Arthritis Patients, Inflammopharmacology (2019)
5. Β-D-Mannuronic Acid (M2000) As a Landmark in Pharmacology, Current Drug Discovery Technologies (2021)
6. Anti-Diabetic Effect of Β-D-Mannuronic Acid (M2000) As a Novel Nsaid With Immunosuppressive Property on Insulin Production, Blood Glucose, and Inflammatory Markers in the Experimental Diabetes Model, Archives of Physiology and Biochemistry (2019)
7. A Phase I/Ii Randomized, Controlled, Clinical Trial for Assessment of the Efficacy and Safety of Β-D-Mannuronic Acid in Rheumatoid Arthritis Patients, Inflammopharmacology (2018)
8. The Role of Β-D-Mannuronic Acid, As a New Non-Steroidal Anti-Inflammatory Drug on Expression of Mir-146A, Irak1, Traf6, Nf-Κb and Pro-Inflammatory Cytokines Following a Clinical Trial in Rheumatoid Arthritis Patients, Immunopharmacology and Immunotoxicology (2020)
Experts (# of related papers)
View all Related Experts
Mahdi Mahmoudi (8)
Mostafa Hosseini (8)
Other Related Docs
9. The Oral Administration Effect of Drug Mannuronic Acid (M2000) on Gene Expression of Matrix and Tissue Inhibitor of Metalloproteinases in Rheumatoid Arthritis Patients, Current Drug Discovery Technologies (2020)
10. Effect of Β-D-Mannuronic Acid (M2000) on Oxidative Stress Enzymes’ Gene Using Healthy Donor Peripheral Blood Mononuclear Cells for Evaluating the Anti-Aging Property, Current Drug Discovery Technologies (2019)
11. Modification of Sexual Hormones in Rheumatoid Arthritis Patients by M2000 (Β-D-Mannuronic Acid) As a Novel Nsaid With Immunosuppressive Property, Endocrine# Metabolic and Immune Disorders - Drug Targets (2018)
12. Anti-Angiogenesis Effect of Β-D-Mannuronic Acid (M2000) As a Novel Nsaid With Immunosuppressive Properties Under Experimental Model, Clinical and Experimental Pharmacology and Physiology (2018)
13. The Potent Inhibitory Effect of Β-D-Mannuronic Acid (M2000) As a Novel Nsaid With Immunosuppressive Property on Anti-Cyclic Citrullinated Peptide Antibodies, Rheumatoid Factor and Antidsdna Antibodies in Patients With Rheumatoid Arthritis, Current Drug Discovery Technologies (2017)
14. Immunopharmacological Effect of Β-D-Mannuronic Acid (M2000), As a New Immunosuppressive Drug, on Gene Expression of Mir-155 and Its Target Molecules (Socs1, Ship1) in a Clinical Trial on Rheumatoid Arthritis Patients, Drug Development Research (2020)
15. A Controlled, Randomized Phase Ii Clinical Trial for Efficacy and Safety Evaluation of Mannuronic Acid in Secondary Progressive Form of Multiple Sclerosis, International Journal of Neuroscience (2022)
16. Anti-Tumor Effect of M2000 (Β-D-Mannuronic Acid) on the Expression of Inflammatory Molecules in the Prostate Cancer Cell, Immunopharmacology and Immunotoxicology (2021)
17. Β-D-Mannuronic Acid (M2000) and Inflammatory Cytokines in Covid-19; an in Vitro Study, Iranian Journal of Allergy# Asthma and Immunology (2022)
18. Immunotherapeutic Effects of Β-D Mannuronic Acid on Il-4, Gata3, Il-17 and Rorc Gene Expression in the Pbmc of Patients With Inflammatory Bowel Diseases, Iranian Journal of Allergy# Asthma and Immunology (2018)
19. Preclinical Assessment of Β - D -Mannuronic Acid (M2000) As a Non-Steroidal Anti-Inflammatory Drug, Immunopharmacology and Immunotoxicology (2015)
20. Pharmacological Effects of Β-D-Mannuronic Acid (M2000) on Mir-146A, Irak1, Traf6 and Nf-Κb Gene Expression, As Target Molecules in Inflammatory Reactions, Pharmacological Reports (2017)
21. Targeting of Circulating Th17 Cells by Β-D-Mannuronic Acid (M2000) As a Novel Medication in Patients With Rheumatoid Arthritis, Inflammopharmacology (2018)
22. Clinical Improvement of Diabetes Mellitus Type 1 by Β-D-Mannuronic Acid (M2000) in a Breast Cancer Patient - As a Case Report, Clinical Diabetology (2019)
23. The Effects of Mannuronic Acid on Il-1Β, Il-17A, Stat1, and Stat3 Gene Expressions and Tlr2 and Tlr4 Molecules in Multiple Sclerosis, Journal of Clinical Pharmacology (2022)
24. The Effects of Β-D-Mannuronic Acid (M2000), As a Novel Nsaid, on Cox1 and Cox2 Activities and Gene Expression in Ankylosing Spondylitis Patients and the Murine Monocyte/Macrophage, J774 Cell Line, Inflammopharmacology (2018)
25. The Potent Suppressive Effect of Β-D-Mannuronic Acid (M2000) on Molecular Expression of the Tlr/Nf-Kb Signaling Pathway in Ankylosing Spondylitis Patients, International Immunopharmacology (2017)
26. Effects of Β-D-Mannuronic Acid, As a Novel Non-Steroidal Anti-Inflammatory Medication Within Immunosuppressive Properties, on Il17, Rorγt, Il4 and Gata3 Gene Expressions in Rheumatoid Arthritis Patients, Drug Design# Development and Therapy (2017)
27. Hematological Improvement of Patients With Active Rheumatoid Arthritis by Β-D-Mannuronic Acid (M2000) As a Novel Nsaid With Immunosuppressive Property, Iranian Journal of Allergy# Asthma and Immunology (2017)
28. Oral Administration Effects of Β-D-Mannuronic Acid (M2000) on Th17 and Regulatory T Cells in Patients With Ankylosing Spondylitis, Biomedicine and Pharmacotherapy (2018)
29. The Biology of Β-D-Mannuronic Acid (M2000) on Human Dendritic Cell Based on Microrna-155 and Microrna-221, Current Drug Discovery Technologies (2017)
30. Introduction of Β-D-Mannuronic Acid (M2000) As a Novel Nsaid With Immunosuppressive Property Based on Cox-1/Cox-2 Activity and Gene Expression, Pharmacological Reports (2017)
31. Anti‐Inflammatory and Anti‐Tumor Effects of Α-L-Guluronic Acid (G2013) on Cancer-Related Inflammation in a Murine Breast Cancer Model, Biomedicine and Pharmacotherapy (2018)
32. Cardioprotective Effect of Β-D-Mannuronic Acid (M2000) As a Novel Nsaid on Gene Expression of Oxldl Scavenger Receptors in the Experimental Diabetic Model, Immunopharmacology and Immunotoxicology (2018)
33. Efficacy of Β-D-Mannuronic Acid [M2000] on the Pro-Apoptotic Process and Inflammatory-Related Molecules Nfҡb, Il-8 and Cd49d Using Healthy Donor Pbmc, Current Drug Discovery Technologies (2020)
34. Effects of Mannuronic Acid (M2000) on Gene Expression Profile of Signal Transducer and Activator of Transcription Proteins (Stats) in Rheumatoid Arthritis Patients, Reumatismo (2020)
35. Evaluating Mannuronic Acid Effect on Gene Expression Profile of Inflammatory Mediators in Rheumatoid Arthritis Patients, Iranian Journal of Allergy# Asthma and Immunology (2022)
36. The Effect of Β-D-Mannuronic Acid in Animal Model of Epilepsy, Natural Product Communications (2020)
37. Evaluation of the Effect of Mannuronic Acid As a Novel Nsaid With Immunosuppressive Properties on Expression of Socs1, Socs3, Ship1, and Traf6 Genes and Serum Levels of Il-6 and Tnf-Α in Patients With Multiple Sclerosis, Journal of Clinical Pharmacology (2021)
38. Effects of M2000 (D -Mannuronic Acid) on Learning, Memory Retrieval, and Associated Determinants in a Rat Model of Alzheimer's Disease, American Journal of Alzheimer's Disease and other Dementias (2017)
39. Evaluation of Cell Adhesion Molecules (Lfa-1 and L-Selectin) in Ankylosing Spondylitis Patients After Treatment With ß-D-Mannuronic Acid (M2000), Indian Journal of Medical Research (2023)
40. The Inhibitory Role of M2000 (Β-D-Mannuronic Acid) on Expression of Toll-Like Receptor 2 and 4 in Ht29 Cell Line, Recent Patents on Inflammation and Allergy Drug Discovery (2019)
41. M2000 (Β-D-Mannuronic Acid) As a Novel Antagonist for Blocking the Tlr2 and Tlr4 Downstream Signalling Pathway, Scandinavian Journal of Immunology (2017)
42. Immunomodulatory Effects of M2000 (Β-D-Mannuronic Acid) on Tnf-Α, Il-17 and Foxp3 Gene Expression in Patients With Inflammatory Bowel Disease, International Immunopharmacology (2017)
43. Modulation of Macrophage Polarization for Bone Tissue Engineering Applications, Iranian Journal of Allergy# Asthma and Immunology (2018)
44. Blockage of Immune Checkpoint Molecules Increases T-Cell Priming Potential of Dendritic Cell Vaccine, Immunology (2020)
45. Evaluation of the Efficacy and Safety of Β-D-Mannuronic Acid in Patients With Ankylosing Spondylitis: A 12-Week Randomized, Placebo-Controlled, Phase I/Ii Clinical Trial, International Immunopharmacology (2018)
46. Efficient Roles of Mir-146A in Cellular and Molecular Mechanisms of Neuroinflammatory Disorders: An Effectual Review in Neuroimmunology, Immunology Letters (2021)
47. Dysregulated Mirnas Network in the Critical Covid-19: An Important Clue for Uncontrolled Immunothrombosis/Thromboinflammation, International Immunopharmacology (2022)
48. Concomitant Blockade of A2ar and Ctla-4 by Sirna-Loaded Polyethylene Glycol-Chitosan-Alginate Nanoparticles Synergistically Enhances Antitumor T-Cell Responses, Journal of Cellular Physiology (2020)
49. Evaluation of G2013 (Α-L-Guluronic Acid) Efficacy on Pc-3 Cells Through Inhibiting the Expression of Inflammatory Factors, Clinical and Experimental Pharmacology and Physiology (2022)
50. Evaluation of the Effect of Α-L-Guluronic Acid (G2013) on Cox-1, Cox-2 Activity and Gene Expression for Introducing This Drug As a Novel Nsaid With Immunomodulatory Property, Recent Patents on Inflammation and Allergy Drug Discovery (2018)